We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
Location: France, Auvergne-Rhône-Alpes, Écully
Employees: 11-50
Total raised: $218M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | Kurma Part... | kurmapartn... |
| 23.09.2021 | Andera Par... | anderapart... |
| 16.11.2021 | Turenne Ca... | turennecap... |
| - | OrbiMed | orbimed.co... |
| - | Life Scien... | lspvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.01.2023 | Series C | $138M | Novo Holdi... |
| 16.09.2021 | Series B | $80M | Andera Par... |
Mentions in press and media 24
| Date | Title | Description |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion Wed, Oct 22, 2025 09:20 CET Report this content Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 26.04.2025 | Granite Bio: A New Force in Immunology with $100 Million Backing | Granite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro... |
| 25.04.2025 | Granite Bio: Immunology Company Debuts With $100 Million In Funding | Granite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio... |
| 10.10.2024 | Kurma Partners: First Closing Of €250 Million Biofund IV | Kurma Partners, an asset manager focused on improving human health, announced that it has raised EUR 140 million, completing the first closing of Biofund IV. By the final closing in 2025, Kurma aims to have raised a total of €250 million in... |
| 18.09.2024 | Brenus Pharma: A New Dawn in Cancer Vaccines | In the world of biotechnology, every breakthrough is a beacon of hope. Brenus Pharma, a Lyon-based biotech company, has recently raised €22.2 million (approximately $25 million) in a Series A funding round. This infusion of capital is not j... |
| 18.09.2024 | Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines | Brenus Pharma, a French biotech company specializing in the development of cancer vaccines, announced the completion of a €22.2 million Series A financing round. The round is led by Angelor, an investment fund bringing together a cluster of... |
| 15.07.2024 | AstraZeneca Closes Acquisition of Amolyt Pharma | Amolyt Pharma, an Ecully, France global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, announced that its previously announced acquisition by global pharmac... |
| 15.07.2024 | Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca | Andera Partners, a leading European private equity player, announced today that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and r... |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results Thu, Apr 25, 2024 08:00 CET Report this content AstraZeneca 25 April 2024 Q1 2024 results Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery Revenue and EPS summary Q1 2024 % ... |
| 26.03.2024 | 10 French startups to watch in 2024 | In 2023 French companies raised €8.4 billion over 410 deals. According to our Annual report, France took third place among countries by the total raised amount. The companies within the energy sector contributed the most to the numbers, wit... |
Show more